Skip to main content

Table 4 Efficacy endpoints

From: Robenacoxib versus meloxicam for the management of pain and inflammation associated with soft tissue surgery in dogs: a randomized, non-inferiority clinical trial

Variable Group Estimate Standard error 95% Confidence limits P value ANOVA/RMANOVA P value Mann–Whitney U
Lower Upper
Primary endpoint        
Modified GCPS score (without B) Robenacoxib 1.65 0.12 1.42 1.90 0.12 0.29
Meloxicam 1.97 0.18 1.63 2.35   
Unmodified GCPS score (with B) Robenacoxib 2.35 0.17 2.03 2.71 0.13 0.72
Meloxicam 2.79 0.26 2.31 3.34   
Secondary endpoints        
Pain at rest Robenacoxib 2.62 0.31 2.06 3.28 0.20 0.54
Meloxicam 3.30 0.49 2.43 4.39   
Pain at palpation/manipulation Robenacoxib 4.34 0.53 3.39 5.50 0.28 0.71
Meloxicam 5.29 0.84 3.82 7.19   
Global efficacy score Robenacoxib 0.45 0.06 0.33 0.58 0.28 0.22
Meloxicam 0.56 0.09 0.39 0.76   
Global inflammation score Robenacoxib 1.11 0.25 0.66 1.67 0.12 0.59
Meloxicam 1.76 0.42 1.04 2.74   
Owner assessment: demeanor Robenacoxib 0.10 0.02 0.07 0.13 0.96 0.62
Meloxicam 0.10 0.02 0.06 0.14   
Owner assessment: mobility Robenacoxib 0.10 0.03 0.05 0.16 0.17 0.098
  Meloxicam 0.05 0.03 -0.01 0.12   
  1. GCPS = Glasgow Composite Pain Scale.
  2. Data are ANOVA or RMANOVA estimates for group means, standard errors and confidence intervals. P values for group comparisons are from ANOVA or RMANOVA and Mann–Whitney U tests.